Page 2 - Lilly Media News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
kpcnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kpcnews.com Daily Mail and Mail on Sunday newspapers.
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
News provided by
Share this article
MiNA Therapeutics Logo
INDIANAPOLIS and LONDON, May 11, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA s proprietary small activating RNA (saRNA) technology platform.
Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly s key therapeutic focus areas. Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration. MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
May 6, 2021 GMT
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, May 6, 2021 /PRNewswire/ With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies – DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche – to advance connected solutions and streamline care for people living with diabetes in markets outside of the United States. These companies offer unique diabetes management platforms that will be compatible with Lilly’s Tempo Pen™ (approved in several global markets) and Tempo Smart Button™ (currently in late-stage development) to support peo